HAPPE® is a proprietary orthopedic biomaterial and manufacturing process platform for creating bone-integrating implants that look and act like a biologic, by actively participating in the healing process. The HAPPE INTEGRATE®-C cervical interbody spinal fusion system has been commercialized for clinical validation of the HAPPE platform. The INTEGRATE-C has shown the potential to accelerate healing to less than one-half the time of the current standard of care.
HAPPE (Hydroxyapatite Porous Polyetheretherketone) looks and acts like a biologic, due to having bone-like microporosity with hydroxyapatite embedded and exposed on surfaces. The HAPPE platform is protected by 11 issued patents across the biomaterial, manufacturing process, and implant designs. HAPPE has been cleared by the FDA through a 510(k) pathway established for future products. HAPPE has been validated by three preclinical studies, clinical outcomes from more than 1000 patients to date, and strong commercial traction. HAPPE is scalable for future growth across all orthopedic market segments.